Toward this, the genetic alterations implicated in NSCLC involve exon 19 deletions, exon 21 substitution (L858R), exon 20 insertion, L861Q, G719X, and S768I of EGFR; rearrangement, insertion, and point mutations of ALK; rearrangements of ROS1, RET, NTRK, and NRG1; exon 14-skipping mutation and amplification of MET; overexpression of PD-1 or PD-L1; G12C/V/D/A point mutations in KRAS; and homo/hetero-dimerization, amplification of HER2 or mutations in HER2/ERBB [27,67,68]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.